NCT03849339View on ClinicalTrials.gov

Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 Under Fed Condition

PHASE1UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 28, 2019

Primary Completion Date

February 21, 2019

Study Completion Date

February 28, 2019

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

CKD-387

Test drug

DRUG

D635

Reference drug

Trial Locations (1)

03722

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY